Skip to main content
Equibles

RDY · Dr Reddys Laboratories Ltd · Metrics

Track RDY — free

Use RDY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RDY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$11.90 +0.19 (+1.62%) At close · Sep 11
Rebalance outlook locked
Market Cap
$9.91B
Shares
832.99M

RDY metrics

57 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$11.90
Market cap
$9.91B

Price action

20 metrics
Price change (1W)
-0.6%
Price change (30D)
-3.0%
Price change (3M)
-10.5%
Price change (6M)
-15.8%
Price change (YTD)
-15.2%
Price change (1Y)
-19.2%
Trailing year
Price change (5Y)
—
52-week high
$15.38
52-week low
$11.38
Change from 52-week high
-22.6%
Change from 52-week low
+4.6%
Annualized volatility
26.6%
Annualized volatility (3M)
33.0%
Beta
0.2
RSI (14D)
40.5
Price vs SMA 50
-3.9%
Price vs SMA 200
-11.3%
Avg volume (3M)
2.82M
Relative volume
1.1
Average dollar volume
$36.14M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
832.99M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.5
reciprocal yield 40.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
0.7%
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
$0.08
Dividend growth YoY
-8.8%
Dividend growth streak
1
Last ex-dividend
2026-07-24

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-09-30

Profitability

9 metrics
Gross margin
52.8%
Operating margin
15.0%
Trailing 12 months
Net margin
12.8%
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$451.76

Growth

11 metrics
Revenue growth YoY
+3.2%
Year over year
Net income growth YoY
-24.2%
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
-24.1%
Shares change YoY
+0.0%
Year over year · more shares
Revenue CAGR (3Y)
+11.0%
Revenue CAGR (5Y)
+12.1%
EPS CAGR (3Y)
-1.7%
EPS CAGR (5Y)
+19.9%
FCF CAGR (3Y)
-11.1%
FCF CAGR (5Y)
+5.2%

Quality

14 metrics
Return on equity
11.4%
Return on assets
7.4%
Debt / equity
—
Current ratio
1.8
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$163.79M
Total assets
$6.17B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
240
13F filer change QoQ
-11
Institutional ownership
15.1%

Short interest

3 metrics
Short interest
2.9%
Latest settlement · 11.0 days to cover
Days to cover
11.0d
Short-squeeze score
59 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1135951 CUSIP 256135203 13F (30d) 49 filings 49 filers Visit website Investor relations